

ASX Announcement
28 October 2024 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX:OIL)

Optiscan Participates in Major US Industry Events

Optiscan's demonstration of its MedTech at recent and upcoming US healthcare sector events is a critical component of the Company's American market penetration strategy

Highlights

- Optiscan's leadership team participates in recent and upcoming US-based healthcare industry events.
- The ViewnVivo® device was recently demonstrated at the 24-26 October 2024 **American College of Veterinary Surgeons** Surgery Summit.
- Optiscan will also soon be participating at three other upcoming major US healthcare events:
 - ❖ The **American College of Veterinary Pathologists** Annual Meeting in Seattle, Washington.
 - ❖ The **Mayo Clinic Beahrs Surgical Innovation Summit** in Rochester, Minnesota.
 - ❖ The **American Society for Cell Biology** Annual Meeting in San Diego, California.

28 October 2024, Melbourne, Australia – Optiscan Imaging Ltd (ASX: OIL) ('Optiscan' or 'the Company') is pleased to provide details of appearances by members of the Company's leadership team at recent and upcoming US-based healthcare industry events.

As a package, these appearances highlight the Company's progress in achieving one of its key stated objectives, which is the strengthen its presence in the targeted lucrative US market, in the process demonstrating its leadership in real-time, non-invasive digital imaging technologies that have applications across a large and growing number of market segments.

ViewnVivo® showcases its veterinary science applications

Optiscan recently demonstrated its ViewnVivo® device at the 24-26 October 2024 **American College of Veterinary Surgeons** Surgery Summit, held in Phoenix, Arizona. This device incorporates a system designed for life sciences research, which offers veterinary surgeons real-time, live cellular imaging, allowing them to conduct diagnostic and surgical procedures with high precision. Such a capability is currently lacking in the veterinary space.

Putting ViewnVivo® through its paces in front of veterinary surgeons is a prelude to Optiscan's expansion into the veterinary market with an imaging system built specifically for that market's needs.

Optiscan to appear at other upcoming US healthcare events over late calendar 2024

Looking ahead, Optiscan will be engaging with veterinary pathologists at the 16-19 November 2024 **American College of Veterinary Pathologists** Annual Meeting in Seattle, Washington, demonstrating the Company's digital pathology capabilities. Veterinary researchers and pathologists, particularly in oncology, have shown strong interest in ViewnVivo®'s ability to deliver high-resolution, non-invasive insights into disease progression, making it a powerful tool for cancer research and veterinary diagnostics.

In another key event, Optiscan CEO, Dr Camile Farah will join industry leaders at the 7 November 2024 **Mayo Clinic Beahrs Surgical Innovation Summit** in Rochester, Minnesota. The Beahrs Surgical Innovation Summit is an invite-only event that brings together executives and thought leaders within each facet of industry, including multinational and global MedTech companies, startups, and venture capital firms. Dr Farah will participate in a panel discussion titled 'Anatomy of a Deal,' where he will share insights into Optiscan's collaborations with the major US healthcare institution, the Mayo Clinic, and the transformative potential of the Company's imaging technology as its stand-alone imaging system for minimally invasive robotic surgery continues to evolve.

Closing the year, Optiscan will participate in the 14-18 December 2024 **American Society for Cell Biology** Annual Meeting, in San Diego, California. Optiscan will showcase how its cutting-edge technology supports pre-clinical life sciences researchers, particularly in oncology and drug discovery, allowing for real-time, in vivo cellular imaging that drives faster, more accurate medical research insights.

Optiscan CEO and Managing Director, Dr. Camile Farah, commented: *"Recent and upcoming appearances by Optiscan leadership team members at major US healthcare industry events are a critical part of our efforts to penetrate the lucrative target American market. As a group, they give American surgeons, pathologists and researchers the opportunity to get up close and personal with our innovative, non-invasive imaging technology offerings that are now well and truly into their development journeys. These healthcare professionals are coming to realise that our innovative advanced imaging MedTech platform has a wide range of applications spanning minimally invasive surgery, veterinary medicine, and life sciences biomedical research. These events have and will continue to help us show beyond a shadow of a doubt that our target of bridging the gap between surgery and pathology is now becoming a reality."*

– ends –

For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: ceo@optiscan.com

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: julia@thecapitalnetwork.com.au

Optiscan Imaging Ltd (ASX:OIL)

16 Miles St, Mulgrave VIC 3170, Australia • www.optiscan.com • ABN: 81 077 771 987

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.